Medicare Enrolled
Dr. David Filsoof, MD
Cardiovascular Disease · Beverly Hills, CA
Practice pattern: Clinical Cardiology
— Primarily office-based clinical cardiology
Speaking/Promotional
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Filsoof from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Filsoof?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Filsoof
Dr. David Filsoof is a cardiovascular disease specialist in Beverly Hills, CA, with 18 years of NPI registration. Based on federal Medicare data, Dr. Filsoof performed 11,402 Medicare services across 4,977 unique beneficiaries.
Between the years covered by Open Payments, Dr. Filsoof received a total of $89,911 from 65 pharmaceutical and/or device companies across 866 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in cardiovascular disease. The majority of payments are for speaking programs and promotional activities, reflecting participation in industry-sponsored events. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Filsoof is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 18 years in practice
▲ Top 5% volume in CA
$89,911 industry payments
Medicare Practice Summary
Medicare Utilization ↗11,402
Medicare services
Top 5% in CA for cardiovascular disease
4,977
Unique beneficiaries
$112
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~633 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
3,401 | $67 | $168 |
| Hospital follow-up visit, high complexity Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter. |
1,860 | $102 | $254 |
| Regadenoson injection (Lexiscan) for heart stress test An injection of regadenoson, a medication used to stress the heart during diagnostic testing. |
661 | $40 | $475 |
| Remote patient monitoring management, 20 min/month Management based on results from remote vital sign monitoring for the first 20 minutes per calendar month. |
651 | $42 | $128 |
| Remote patient monitoring device, 30 days Initial setup of devices for remote monitoring of body functions with daily data transmission or alerts. This service covers the first 30 days of the monitoring period. |
647 | $45 | $128 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
569 | $147 | $440 |
| Electrocardiogram (EKG), 12-lead A standard heart rhythm test using at least 12 leads to record electrical activity. A healthcare provider interprets the results and provides a written report. |
430 | $12 | $40 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
385 | $67 | $205 |
| Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries | 335 | $415 | $1,040 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
314 | $102 | $284 |
| Echocardiogram, transthoracic An ultrasound of the heart that uses color to show blood flow, rate, direction, and valve function. |
299 | $177 | $483 |
| Advance care planning consultation, first 30 min A session focused on discussing and documenting future healthcare preferences and goals. This service covers the initial 30 minutes of the planning discussion. |
274 | $70 | $185 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
232 | $145 | $400 |
| Initial hospital admission, moderate complexity Initial hospital inpatient or observation care for a new patient involving moderate-level medical decision making, with at least 55 minutes total time on the date of the encounter. |
223 | $109 | $295 |
| New patient office visit, complex (60-74 min) | 173 | $178 | $485 |
| Nuclear stress test with CT scan A nuclear medicine imaging test that evaluates blood flow in the heart muscle at rest and during stress, performed alongside a concurrent CT scan. |
165 | $1,691 | $4,958 |
| PET scan of heart muscle blood flow A nuclear medicine imaging test that uses positron emission tomography (PET) to evaluate blood flow within the heart muscle. |
165 | $110 | $278 |
| Exercise or drug-induced heart stress test with ECG A heart stress test performed using exercise or medication while monitoring the electrocardiogram under physician supervision and review. |
154 | $60 | $205 |
| Office visit, established patient (10-19 min) An office visit for an existing patient lasting 10 to 19 minutes. The visit involves medical evaluation and management of the patient's condition. |
129 | $42 | $125 |
| Exercise or drug-induced heart stress test with ECG A test that monitors the heart's electrical activity while the patient exercises or receives medication to increase heart rate. |
102 | $34 | $85 |
| Remote physiologic monitoring setup and education Initial setup of remote monitoring equipment and patient education on its use. |
67 | $18 | $38 |
| Aminophylline injection, up to 250 mg Administration of aminophylline medication via injection for a dose of up to 250 mg. |
41 | $8 | $25 |
| Ultrasound of head and neck blood flow, bilateral An ultrasound exam that uses sound waves to visualize and assess blood flow in the vessels of both the head and the neck. |
37 | $178 | $475 |
| Critical care, first 30-74 min Emergency medical care for a critically ill or injured patient lasting between 30 and 74 minutes. This service involves direct patient care and medical decision making to stabilize the patient. |
24 | $181 | $610 |
| Telephone medical discussion, 11-20 minutes A phone conversation with a physician lasting between 11 and 20 minutes. |
21 | $79 | $200 |
| Continuous external EKG monitoring, 48 hours to 7 days This procedure involves recording the heart's electrical activity continuously using an external device for a period exceeding 48 hours but not more than 7 days. |
15 | $9 | $35 |
| Continuous EKG monitoring review, 48-7 days Review and interpretation of continuous external EKG recordings lasting more than 48 hours up to 7 days. |
15 | $19 | $55 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
13 | $143 | $362 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
2.6% high complexity
10.2% medium
87.2% routine
Industry Payment Transparency
Open Payments through 2024 ↗$89,911
Total received (2018-2024)
Avg $12,844/year across 7 years
Top 7% in CA for cardiovascular disease
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
65
Companies
866
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$73,385 (81.6%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$16,527 (18.4%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$41,037
2023
$27,793
2022
$5,343
2021
$6,161
2020
$5,901
2019
$2,288
2018
$1,388
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Novo Nordisk Inc
$17,491
Boehringer Ingelheim Pharmaceuticals, Inc.
$11,338
Amgen Inc.
$6,220
ZOLL Services LLC (A/K/A ZOLL LifeCor Corp)
$2,788
Lilly USA, LLC
$568
HEARTFLOW, INC.
$454
Novartis Pharmaceuticals Corporation
$422
Kiniksa Pharmaceuticals International, plc
$272
Salix Pharmaceuticals, a division of Bausch Health US, LLC
$239
Phathom Pharmaceuticals, Inc.
$178
Lexicon Pharmaceuticals, Inc.
$147
Edwards Lifesciences Corporation
$111
Bayer Healthcare Pharmaceuticals Inc.
$94
Cleerly, Inc.
$94
E.R. Squibb & Sons, L.L.C.
$89
Esperion Therapeutics, Inc.
$82
AstraZeneca Pharmaceuticals LP
$81
AIMMUNE THERAPEUTICS, INC.
$65
Janssen Biotech, Inc.
$65
Daiichi Sankyo Inc.
$51
PFIZER INC.
$50
Boston Scientific Corporation
$24
Ipsen Biopharmaceuticals, Inc
$24
Regeneron Healthcare Solutions, Inc.
$21
Alnylam Pharmaceuticals Inc.
$19
Janssen Pharmaceuticals, Inc
$19
Radius Health, Inc.
$17
Itamar Medical Inc
$14
Top 3 companies account for 85.4% of 2024 payments
All-time payments by company (2018-2024) ›
Amgen Inc.
$19,150
Boehringer Ingelheim Pharmaceuticals, Inc.
$18,533
Novo Nordisk Inc
$17,846
ZOLL Services LLC (A/K/A ZOLL LifeCor Corp)
$11,124
Genentech USA, Inc.
$4,524
Boston Scientific Corporation
$2,644
BOSTON SCIENTIFIC CORPORATION
$1,948
Lilly USA, LLC
$1,636
Novartis Pharmaceuticals Corporation
$1,409
Janssen Pharmaceuticals, Inc
$1,243
Salix Pharmaceuticals, a division of Bausch Health US, LLC
$1,232
Abbott Laboratories
$820
HeartFlow, Inc.
$808
PFIZER INC.
$558
HEARTFLOW, INC.
$454
AstraZeneca Pharmaceuticals LP
$453
Amarin Pharma Inc.
$441
Edwards Lifesciences Corporation
$419
Teva Pharmaceuticals USA, Inc.
$357
E.R. Squibb & Sons, L.L.C.
$299
Esperion Therapeutics, Inc.
$277
Kiniksa Pharmaceuticals International, plc
$272
Kiniksa Pharmaceuticals, Ltd.
$227
Otsuka America Pharmaceutical, Inc.
$215
Daiichi Sankyo Inc.
$213
Itamar Medical Inc
$211
Janssen Biotech, Inc.
$192
Regeneron Healthcare Solutions, Inc.
$179
Phathom Pharmaceuticals, Inc.
$178
Lexicon Pharmaceuticals, Inc.
$167
Merck Sharp & Dohme LLC
$146
Nestle HealthCare Nutrition Inc.
$132
Biohaven Pharmaceutical Holding Company Ltd.
$130
NESTLE HEALTHCARE NUTRITION INC.
$129
Alnylam Pharmaceuticals Inc.
$118
Bayer Healthcare Pharmaceuticals Inc.
$115
Kestra Medical Technology Services, Inc.
$98
Ardelyx, Inc.
$94
Cleerly, Inc.
$94
Bayer HealthCare Pharmaceuticals Inc.
$85
Biohaven Pharmaceuticals, Inc.
$74
ABBVIE INC.
$66
AIMMUNE THERAPEUTICS, INC.
$65
EVOKE PHARMA, INC.
$47
GlaxoSmithKline, LLC.
$43
Kowa Pharmaceuticals America, Inc.
$41
Baxter Healthcare
$38
Medtronic, Inc.
$26
Actelion Pharmaceuticals US, Inc.
$25
Ipsen Biopharmaceuticals, Inc
$24
iRhythm Technologies, Inc.
$23
Alexion Pharmaceuticals, Inc.
$23
SANOFI-AVENTIS U.S. LLC
$23
Myovant Sciences Inc.
$22
Retrophin, Inc.
$22
ARBOR PHARMACEUTICALS, INC.
$21
SCPHARMACEUTICALS INC.
$20
QOL Medical, LLC
$20
Merck Sharp & Dohme Corporation
$19
Takeda Pharmaceuticals U.S.A., Inc.
$19
Janssen Scientific Affairs, LLC
$18
Radius Health, Inc.
$17
Evofem Biosciences, Inc.
$17
Arbor Pharmaceuticals, Inc.
$15
Biocompatibles, Inc.
$13
Top 3 companies account for 61.8% of all-time payments
Associated products mentioned in payments ›
(815) Thiola · AJOVY · AMVUTTRA · ANDEXXA · Aimovig · Arcalyst · Assure WCD · BREZTRI · BRILINTA · CAMZYOS · COMIRNATY · Cleerly Ischemia · Corlanor · DIFICID · DUPIXENT · ELIQUIS · ENTRESTO · ENTYVIO · Edarbi · Edwards SAPIEN 3 Transcatheter Heart Valve · Edwards SAPIEN 3 Ultra Transcatheter Heart Valve · FARXIGA · FFRct · FUROSCIX · GIMOTI · GIVLAARI · Hillrom - Cardiac Ambulatory Monitor · IBSRELA · INJECTAFER · IQIRVO · Inpefa · JARDIANCE · JYNARQUE · Kerendia · LEQVIO · LOKELMA · LifeVest · Livalo · MITRACLIP · MOUNJARO · MYFEMBREE · Mitra Clip system · MitraClip System · NEXLETOL · NEXLIZET · NURTEC ODT · OFEV · OPSUMIT · Otezla · Ozempic · PAXLOVID · PLENVU · PRALUENT · PRALUENT ALIROCUMAB INJECTION · PROCLAIM · Parsabiv · Phexxi · QULIPTA · RELISTOR · RYBELSUS · Repatha · Rybelsus · SAPIEN 3 Ultra RESILIA · SHINGRIX · SPIRIVA RESPIMAT · STELARA · STIOLTO RESPIMAT · SUCRAID · Saxenda · TRULANCE · TRULICITY · TYRX · UBRELVY · VARITHENA · VERQUVO · VOQUEZNA · VOWST · VYNDAQEL · Vascepa · Verquvo · WAINUA · WATCHMAN · WATCHMAN Access System · WATCHMAN FLX · WatchPAT · WatchPATONE · Wegovy · XARELTO · XIFAXAN · Xofluza · ZENPEP · ZEPBOUND · ZIO XT Patch
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
The majority of payments (82%) are for speaking programs and promotional activities, which reflect participation in industry-sponsored educational or marketing events. This is common in cardiovascular disease and does not inherently indicate bias, but patients may wish to be aware. Total industry engagement is in the top 7% for cardiovascular disease in CA.
Geographic Context
Cardiologists within 10 mi
584
Per 100K population
5.9
County median income
$87,760
Nearest hospital
CEDARS-SINAI MEDICAL CENTER
0.8 mi
0.8 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Filsoof is a clinical cardiology specialist, with above-average Medicare volume (top 5% in CA), with speaking/promotional industry engagement in the top 7% of CA peers, with 18 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Filsoof experienced with hospital follow-up visit, moderate complexity?
Based on Medicare claims data, Dr. Filsoof performed 3,401 hospital follow-up visit, moderate complexity services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Filsoof receive payments from pharmaceutical companies?
Yes. Dr. Filsoof received a total of $89,911 from 65 companies across 866 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Filsoof's costs compare to other cardiologists in Beverly Hills?
Dr. Filsoof's average Medicare payment per service is $112. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Filsoof) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Cardiologists in Beverly Hills
Browse cardiologists in Beverly Hills ranked by procedure volume and transparency data.
Highest volume
Top Cardiologists in CA
Cardiologists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Cardiologists in CA
Which CA cardiologists receive the most from drug and device companies.
By company
Amgen Inc. Payments to Doctors
See all physicians who received payments from Amgen Inc.
By company
Boehringer Ingelheim Pharmaceuticals, Inc. Payments to Doctors
See all physicians who received payments from Boehringer Ingelheim Pharmaceuticals, Inc.
By company
Novo Nordisk Inc Payments to Doctors
See all physicians who received payments from Novo Nordisk Inc.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology